Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease.

Alzheimer's disease (AD) is a significant 21st-century public health challenge. This article delves into AD's neurodegenerative complexities, highlighting cognitive decline, memory impairment, and societal burdens. Mechanistically, protein misfolding, amyloid-beta (Aß) pathway abnormalities, and genetic/environmental factors are discussed. The pivotal amyloid hypothesis is dissected, focusing on Aß aggregation's role in synaptic dysfunction and neurodegeneration. The review showcases promising therapeutic strategies, including anti-amyloid antibodies and ß/γ-secretase inhibitors targeting Aß production. Notably, the FDA-approved Lecanemab signifies a breakthrough, slowing disease progression. Anti-Tau therapies' emergence is highlighted, addressing late-stage intervention. Tau aggregation blockers and anti-Tau antibodies offer potential against intracellular tau pathology. The review underscores collaborative efforts to uncover AD's secrets and pave the way for memory preservation.

Three-Dimensional Bioprinting in Medicine: A Comprehensive Overview of Current Progress and Challenges Faced.

The shortage of organs for transplantation is a global crisis, with an increasing demand and an inadequate supply of organ donors. The convergence of biology and engineering has led to the emergence of 3D bioprinting, which enables the precise and customizable construction of biological structures. Various 3D bioprinting techniques include inkjet printing, extrusion printing, and laser-assisted bioprinting (LAB). Although it has the potential for many benefits, 3D bioprinting comes with its own set of challenges and requirements, specifically associated with the bioprinting of various tissues. The challenges of bioprinting include issues with cells, bioinks, and bioprinters, as well as ethical concerns, clinical efficacy, and cost-effectiveness, making it difficult to integrate 3D bioprinting into widespread clinical practice. Three-dimensional bioprinting holds great promise in addressing the organ shortage crisis, and its applications extend beyond organ transplantation to include drug screening, disease modeling, and regenerative medicine. However, further research is needed to overcome the technical, biological, and ethical challenges associated with 3D bioprinting, paving the way for its widespread clinical implementation. This article discusses the processes and challenges of bioprinting as well as the current research direction in the field.